Uptera 10 mg/mL Solution for Injection

Valsts: Jordānija

Valoda: angļu

Klimata pārmaiņas: JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

Aktīvā sastāvdaļa:

Ranibizumab 10 mg/ml

Pieejams no:

شركة ام اس فارما - MS Pharma

ATĶ kods:

S01LA04

SNN (starptautisko nepatentēto nosaukumu):

Ranibizumab 10 mg/ml

Deva:

10 mg/ml

Vienības iepakojumā:

1 Vial

Ražojis:

Ajinomoto Althea Incorporated/ USA (امريكا)

Lietošanas instrukcija

Page 1 of 10
PACKAGE LEAFLET: INFORMATION FOR THE ADULT PATIENT
UPTERA® 10 MG/ML SOLUTION FOR INJECTION
INTRAVITREAL USE
Ranibizumab
ADULTS
▼THIS MEDICINE IS SUBJECT TO ADDITIONAL MONITORING. THIS WILL ALLOW
QUICK
IDENTIFICATION OF NEW SAFETY INFORMATION. YOU CAN HELP BY REPORTING
ANY SIDE EFFECTS
YOU MAY GET. SEE THE END OF SECTION 4 FOR HOW TO REPORT SIDE EFFECTS.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE
BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor.
-
If you get any side effects, talk to your doctor. This includes any
possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. WHAT UPTERA® IS AND WHAT IT IS USED FOR
2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN UPTERA®
3. HOW UPTERA® IS GIVEN
4. POSSIBLE SIDE EFFECTS
5. HOW TO STORE UPTERA®
6. CONTENTS OF THE PACK AND OTHER INFORMATION
1. WHAT UPTERA® IS AND WHAT IT IS USED FOR
WHAT UPTERA® IS
Uptera® is a solution which is injected into the eye. Uptera®
belongs to a group of
medicines called antineovascularisation agents. It contains the active
substance called
ranibizumab.
WHAT UPTERA® IS USED FOR
UPTERA® is used in adults to treat several eye diseases causing
vision impairment.
These diseases result from damage to the retina (light-sensitive layer
at the back of the
eye) caused by:
-
Growth of leaky, abnormal blood vessels. This is observed in diseases
such as
age-related macular degeneration (AMD) and proliferative diabetic
retinopathy
(PDR, a disease caused by diabetes). It may also be associated with
choroidal
neovascularisation (CNV) due to pathologic myopia (PM), angioid
streaks,
central serous chorioretinopathy or inflammatory CNV.
-
Macular oedema (swelling of the centre of the retina). This swelling
can be
caused by diabetes (a disease called diabetic macular oedema (DME)) or
by the
blockage of retinal veins of the retina (a disease called retinal vein
occlusion
(RVO))